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In holoendemic Plasmodium falciparum transmission areas such as western Kenya, severe malarial anemia [SMA,
hemoglobin (Hb) < 6.0 g/dL, with any density parasitemia] is the most common clinical manifestation of severe malaria
resulting in high rates of pediatric morbidity and mortality in these regions. Previous studies associated interleukin (IL)-13
with pathogenesis of different infectious diseases, including P. falciparum malaria. However, the functional roles of
polymorphic variants within the IL-13 promoter in conditioning susceptibility to SMA remain largely unexplored. As such,
the association between the IL-13 variants -7402 T/G (rs7719175) and -4729G/A (rs3091307) and susceptibility to SMA was
determined in children (n = 387) presenting with clinical symptoms of falciparum malaria and resident in a holoendemic
transmission region in western Kenya. Our results indicated no difference in the proportions of individual genotypes
among children presenting with non-SMA (n = 222) versus SMA (n = 165). Similarly, there was no associations between
the individual genotypes (−7402 T/G and -4729G/A) and SMA. Additional analyses, however, revealed that proportions of
individuals with -7402 T/-4729A (TA) haplotype was significantly higher in children presenting with SMA than non-SMA
group (P = 0.043). A further multivariate logistic regression analyses, controlling for confounding factors, demonstrated
that carriage of the TA haplotype was associated with increased susceptibility to SMA (OR; 1.564, 95% CI; 1.023-2.389,
P = 0.039). In addition, circulating levels of IL-13 were comparable between the clinical groups as well as across genotypes
and haplotypes. Collectively, findings presented here suggest that haplotypes within the IL-13 promoter at -7402 T/G
and -4729G/A may modulate SMA pathogenesis, but do not affect circulating IL-13 levels.
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Plasmodium malaria is one of the leading causes of mor-
bidity and mortality in the world [1]. World Health
Organization (WHO) estimated that 216 million malaria
episodes occurred in the year 2010, resulting in approxi-
mately 655,000 deaths, of which 91% occurred in the
sub-Saharan Africa [2]. Children under five years of age
bear the greatest disease burden, with a global malaria* Correspondence: collinouma@yahoo.com
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reproduction in any medium, provided the orrelated mortality of 86% documented in 2010 [2]. In
malaria endemic regions of sub-Saharan Africa, greater
than 90% of malaria-related deaths are attributable to
Plasmodium falciparum, the most virulent of the five
malaria parasite species known to cause human malaria
[3]. The clinical spectrum of severe falciparum malaria
often ranges from mild symptoms to life threatening
complications which include, but are not limited to, se-
vere anemia, respiratory distress, cerebral malaria (CM),
hyperparasitemia, metabolic acidosis, kidney failure, and
hypoglycemia [4]. In western Kenya, a falciparum mal-
aria holoendemic region, the most common clinical
manifestation of severe malaria is severe malarial anemia
[SMA (Hb < 6.0 g/dL)], with any density parasitemiaLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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reported only in rare cases [7-9]. In addition, the etiology
of SMA is complicated by the presence of co-infections
and by host genetic factors [9-14]. Furthermore, additional
studies have demonstrated that immunity against SMA is
characterized by dysregulation of innate types 1 and 2 in-
flammatory mediators, mainly cytokines, chemokines and
effector molecules [15-17].
Among the inflammatory mediators implicated in mal-
aria pathogenesis is interleukin (IL)-13, a type 2 cytokine
that shares structural and functional characteristics with
IL-4 [18,19]. IL-13 is a pleiotropic cytokine predominantly
produced by activated T lymphocytes, mast cells, baso-
phils, natural killer (NK) cells and dendritic cells [20]. It
functions as an immune modulator on a wide range of cell
types, including macrophages, NK cells, fibroblasts, eosin-
ophils, airway smooth muscle cells, and endothelial cells
[20]. Elevated levels of IL-13 have been implicated in aller-
gic responses and in parasitic infections [21-23]. Recently,
IL-13 has emerged as a negative predictor of hemoglobin
(Hb) levels for pediatric malarial anemia [17].
The human IL-13 gene has been mapped to the 5q31-
q33 region, located on chromosome 5, which contains
additional genes encoding cytokines, including IL-3, IL-
4, IL-5, IL-9, and IL-12B [24-28]. Polymorphisms in the
promoters of genes coding for these cytokines have been
shown to alter susceptibility to infectious diseases
[11,25,29,30]. Several polymorphic variants identified in
the IL-13 gene region [25,30,31] have been associated
with various diseases including allergic rhinitis [32],
asthma [33], atopic dermatitis [22], and schistosomiasis
[25]. In addition, studies in Thai adults demonstrated
that a single nucleotide polymorphism (SNP) in the IL-
13 promoter (IL-13 -1055C > T) is associated with severe
malaria [31]. However, to date, no studies have reported
the associations between IL-13 promoter variants -
7402G/T (rs7719175) and -4729G/A- (rs3091307), their
haplotype constructs and SMA in pediatric populations
resident in P. falcipuram holoendemic transmission re-
gion such as in western Kenya. The IL-13 promoter vari-
ants -7402G/T (rs7719175) and -4729G/A- (rs3091307)
were selected based on the mutant allele frequency ~10%
in reference African Yoruba population (http://hapmap.
ncbi.nlm.nih.gov/downloads/frequencies/). Consequently,
the current study investigated the associations between
two IL-13 promoter variants, haplotypes and susceptibil-
ity to SMA in a phenotypically well-defined cohort of
children aged 3–36 months presenting with clinical
symptoms of malaria in a rural setting of western Kenya.
Methods
Study site
The study was carried out in Siaya District Hospital
(SDH), a P. falciparum holoendemic transmission regionin western Kenya. Residents in this region are predomin-
antly of the Luo ethnic group (>96%), thus providing a
homogeneous population suitable for a genetic-based
study [5]. Malaria accounts for the highest number of
childhood morbidities and mortalities in this area [6,17].
The major malaria vectors are An. gambiae s.s., An.
arabiensis and An. funestus [34].
Study participants
The study recruited parasitemic patients (n = 387), who
presented with clinical symptoms of malaria at SDH.
Both male and female children aged between 3 and 36 -
months visiting SDH for the first time with symptoms of
malaria qualified for enrollment into the study. Informed
consent to participate in the study was obtained from
the parents/legal guardians of the children. Question-
naires were used to collect relevant geographical and
clinical information. Any patient who had been hospital-
ized before in their lifetime, or who had received anti-
malarial treatment two weeks prior to enrollment was
excluded from the study. Children with CM, though very
rare, and children with non-falciparum malaria were also
excluded from the study. Parasitemic children with Hb
levels of >6.0 g/dL were classified as non-severe malarial
anemia (non-SMA) while those with Hb <6.0 g/dL were
classified as having SMA. This classification was based
on a previous large-scale longitudinal study that exam-
ined the distribution of >14,000 Hb measurements in an
age- and geographically-matched reference population in
western Kenya [35]. The study approval was obtained
from the Ethics Review Committees of the Kenya Med-
ical Research Institute (KEMRI).
Sample processing
For children who met the inclusion criteria, blood sam-
ples from heel or finger pricks (<100μL) were obtained
and used to determine parasite density by preparation of
thick and thin blood smears stained using Giemsa re-
agent. In addition, venous blood, approximately 3 mL,
was collected into EDTA-containing vacutainer tubes.
About 100 μL of blood was bloated onto FTA Classic
cards for use in DNA extraction for genetic analyses. A
complete blood count was carried out using a Beckman
Coulter AcT Diff2 (Beckman-Coulter Inc., Miami, FL)
for hematological parameters including Hb levels, red
blood cell (RBC) counts, hematocrit and mean corpus-
cular volume. Plasma was separated from the remaining
blood, which was snap-frozen at −80 °C until use. Bac-
terial co-infections were investigated by incubation of
blood collected in trypticase soy broth with sodium
polyanethanol sulfonate (SPS) for 18 hours and bacteria
identified by gram staining procedures, colonial charac-
teristics, appearances and biochemical and serological
tests. Sickle-cell status was determined by alkaline
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was determined by a fluorescent spot test using glucose-
6-phosphate and oxidized NADP (NADP+) where sam-
ples were scored as normal (high emission), intermediate
(moderate emission), or deficient (no emission).
DNA extraction
DNA was extracted from the FTA Classic card and filter
papers using the Gentra Systems DNA extraction protocol
(Gentra Systems, Minneapollis, MN, USA). To confirm the
presence of DNA, a house-keeping gene, human glucose-3-
phosphate dehydrogenase (hG3PDH) was amplified.
IL-13 genotyping
Applied Biosystems SNP-specific primer-probe combina-
tions (TaqManW SNP Genotyping Assays, assay ID;
C_31237837_10 and C_27452177_20) were used to
genotype IL-13 -7402 T/G and -4729G/A SNPs, respect-
ively, on the Applied Biosystems StepOnePlus™ Real-
Time PCR System (Applied Biosystems, Foster City, CA,
USA), according to the manufacturer’s instructions.
Cytokine measurements
Plasma IL-13 levels were measured using the enzyme-
linked immunosorbent assay (cytokine-ELISA), on an
ELx800™ Absorbance Microplate Reader (BioTekW In-
struments, Inc. Winooski, VT, USA), according to the
manufacturer’s specifications for IL-13 detection and
levels computed using the Gen5 software (BioTekW In-
struments, Inc. Winooski, VT, USA). The detection limit
for IL-13 was 10 pg/mL.
Data management and analysis
Data analyses were performed using SPSSW statistical soft-
ware package version 19.0 (IBM SPSS Inc., Chicago, IL,
USA). The IL-13 (−7402 T/G and -4729G/A) promoter
haplotypes were constructed using HPlus software program
(Version 2.5). Comparison of proportions between and
within groups was computed using chi-square (χ2). Com-
parison of cytokine and Hb levels across individual IL-13
promoter variants was performed using Kruskal-Wallis test
while pairwise group comparisons was by Mann–Whitney
U test. Association between genotypes/haplotypes and
SMA was determined using the multivariate logistic regres-
sion analyses models, controlling for potential confounders
including age, gender, bacteremia, sickle cell trait (HbAS)
and glucose-6-phosphate dehydrogenase (G6PD) defi-
ciency. Statistical significance was considered at P ≤ 0.050.
Results
Demographic, clinical, and laboratory characteristics of
the study participants
To determine the role of the IL-13 promoter variants
(−7402 T/G and -4729G/A) in conditioning susceptibilityto SMA, children (n = 387), aged 3–36 months presenting
with P. falciparum malaria were categorized into two
groups according Hb levels as non-severe malarial anemia
(non-SMA, Hb ≥ 6.0 g/dL, any density parasitemia; n = 222)
and severe malarial anemia (SMA, Hb < 6.0 g/dL, any
density parasitemia; n = 165). The demographic, clin-
ical, and laboratory characteristics of the study partici-
pants are summarized in Table 1. Proportions of males
versus females in the clinical groups were comparable
(P = 0.862). In addition, IL-13 levels (P = 0.415) and
parasite density (P = 0.530) were also comparable be-
tween the clinical groups. Further analyses revealed
that children in the non-SMA group were significantly
older than those in the SMA group (P < 0.001). As
expected based on stratification, the hematological pa-
rameters, among them Hb, hematocrit, red blood cell
(RBC) count, red blood cell distribution width (RDW)
and mean corpuscular hemoglobin concentration
(MCHC) were all significantly different between the
SMA and non-SMA groups (P < 0.001 in all cases).
Distribution of individual IL-13 promoter variants in the
clinical groups
The overall frequency of the -7402 T/G genotypes were
TT (n = 334, 0.863), TG (n = 49, 0.127) and GG (n = 4,
0.010) (Table 2). There was no significant departure
from Hardy Weinberg Equilibrium in the overall distri-
bution (HWE, χ2 = 2.007, P = 0.157). The distribution
of -7402 T/G variant in the non-SMA (n = 222) and SMA
(n = 165) and the genotype frequencies within the clinical
groups were TT (non-SMA, n = 194, 0.874; SMA, n = 140,
0.848), TG (non-SMA, n = 26, 0.117; SMA, n = 23, 0.139)
and GG (non-SMA, n = 2, 0.009; SMA, n = 2, 0.012).
These distributions were comparable between the SMA
and non-SMA groups (P = 0.767). Additional analyses
demonstrated that Hb levels were comparable across the
genotypic groups (P = 0.744). There was no departure
from HWE at the IL-13 -7402 T/G variant in either the
non-SMA (χ2 = 1.104, P = 0.293) or SMA (χ2 = 0.861,
P = 0.353) groups.
The following were the overall genotypic frequencies at
the -4729G/A locus; GG (n = 205, 0.530), GA (n = 131,
0.339), AA (n = 51, 0.132) (Table 2). Significant departure
from the HWE was observed for this variant in the distri-
bution of genotypes in the overall population (χ2 = 14.810,
P < 0.001). Distributions of the genotypes within the clin-
ical groups were GG (non-SMA, n = 78, 0.473; SMA,
n = 127, 0.572), GA (non-SMA, n = 63, 0.382; SMA, n = 68,
0.306) and AA (non-SMA, n = 24, 0.145; SMA, n = 27,
0.122) and were comparable between the non-SMA
and SMA groups (P = 0.152). In addition, the distribu-
tion of Hb levels were also comparable across the
genotypic groups (P = 0.521). There was significant de-
parture from HWE in the non-SMA group (χ2 = 11.891,
Table 1 Clinical, demographic and laboratory characteristics of the study participants
Characteristics non-SMA (Hb ≥ 6.0 g/dL) SMA (Hb < 6.0 g/dL) P value
No. of participants (n = 387) 222 165
Gender, n (%)
Male 115 (51.8) 84 (50.9) 0.862a
Female 107 (48.2) 81 (49.1)
Age, months 11.0 (10.0) 8.0 (8.0) <0.001b
IL-13 concentration (pg/mL) 31.6(26.5) 35.4(38.07) 0.415b
Parasites/μL 29960.1(40957.8) 20639.1(42359.6) 0.530b
Hematological Parameters
Hemoglobin, g/dL 8.0 (3.0) 4.9 (1.0) <0.001b
Hematocrit,% 24.8 (7.3) 15.8 (5.0) <0.001b
RBCs, × 1012/μL 3.7 (1.2) 2.2 (0.9) <0.001b
RDW,% 17.5 (1.7) 17.9 (1.2) <0.001b
MCHC, g/L 32.3 (2.0) 31.3 (2.7) <0.001b
Data is presented as the median (interquartile range) unless stated otherwise. A total of 387 parasitemic children were categorized as either SMA (n = 165) or non-
SMA (n = 222) based on age- and geographically-matched Hb concentrations in children in western Kenya (Hb < 6.0 g/dL, with any density parasitemia) [35].
aStatistical significance determined by Chi-square (χ2) tests. bStatistical significance determined by Mann–Whitney U test. Abbreviations: RBCs - Red blood cells;
RDW - Red cell distribution width; MCHC - Mean corpuscular hemoglobin concentration.
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SMA group (χ2 = 3.458, P = 0.063).
Association between individual IL-13 promoter
polymorphisms and SMA
To determine the role of individual IL-13 genotypes in con-
ditioning susceptibility to SMA, a multivariate logistic re-
gression analyses were carried out using the wild type in
each variant as the reference group, while controlling for
the confounding effects of age, gender, bacteremia, G6PD
deficiency and sickle-cell trait [10,13,36-38] (Table 3). Rela-
tive to the wild type genotypes (−7402, TT and −4729, GG),
there was no significant association between the individual
promoter variants and susceptibility to SMA at the -
7402 T/G (TG, OR; 1.168, 95% CI, 0.626-2.180, P = 0.625
and GG, OR; 1.871, 95% CI, 0.240-14.597, P = 0.550) and -
4729G/A (AA, OR; 1.484, 95% CI, 0.777-2.835, P = 0.232)
loci. The GA genotype however showed marginalTable 2 The distribution of individual IL-13 promoter genotyp
Genotypes Hemoglobin Levels (g/dL) P value n (%) Non
IL-13 -740
TT 6.4 (3.0) 0.744b 334 (86.3)
TG 6.1 (3.0) 49 (12.7)
GG 6.2 (2.0) 4 (1.0)
IL-13 -472
GG 6.4 (4.0) 0.521b 205(53.0)
GA 6.0 (3.0) 131 (33.9)
AA 6.2 (3.0) 51 (13.2)
Data are presented as [n, (%)] for proportions of IL-13 promoter variants −7402 T >
based on age- and geographically-matched Hb concentrations in children in wester
The Hb levels are presented as medians (IQR), and bKruskal Wallis test was used toassociation with susceptibility to SMA (OR; 1.589, 95% CI,
0.995-2.539, P = 0.052).
Distribution of IL-13 promoter haplotypes in the clinical
groups
Prior to determining the associations between the haplo-
types and SMA, the overall distributions of the different
haplotypes were determined. Results yielded the following
overall distribution, -7402G/-4729G (GG, n = 53/387) were
13.7%, -7402 T/-4729A (TA, n = 181/387) were 46.8% and -
7402 T/-4729G (TG, n = 311) were 80.4% (Table 4).
The distribution of the haplotype carriers in the clinical
groups were as follows (Table 4); GG (non-SMA, n = 28/
222, 12.6%; SMA, n = 25/165, 15.2%) and TG (non-SMA,
n = 183/222, 82.4%; SMA, n = 128/165, 77.6%). These
distributions were not significantly different in the SMA
(P = 0.472) and non-SMA (P = 0.234) groups. However,
the frequency of the TA haplotype was significantly higheres in the clinical groups
-SMA (Hb ≥ 6.0 g/dL) n (%) SMA (Hb < 6.0 g/dL) n (%) P value
2 T > G
194 (87.4) 140(84.8) 0.767a
26 (11.7) 23 (13.9)
2 (0.9) 2 (1.2)
9 A > G
78 (47.3) 127 (57.2) 0.152a
63 (38.2) 68 (30.6)
24 (14.5) 27 (12.2)
G and −4729 G > A within the SMA (n = 165) and non-SMA (n = 222) groups
n Kenya (Hb < 6.0 g/dL, with any density parasitemia) [35]. aChi-square analysis.
compare the levels between the genotypes.
Table 5 The associations between IL-13 promoter
haplotypes and SMA
Haplotypes Odds Ratio 95% CI P value
−7402G/-4729G, (n = 53) 1.211 0.663-2.212 0.533
−7402 T/-4729A, (n = 181) 1.564 1.023-2.389 0.039
−7402 T/-4729G, (n = 311) 0.760 0.449-1.286 0.307
Multivariate logistic regression analyses were used to determine the odds ratio
(OR) and 95% CI, controlling for age, gender, G6PD deficiency, sickle-cell trait
status and presence of bacterial infections [10,13,36-38]. The haplotype non-
carriers were used as reference groups for the analyses in the regression
analyses.
Table 3 The associations between individual IL-13
promoter variants and SMA
Genotypes Odds Ratio 95% CI P value
IL-13 -7402 T > G
TT, (n = 334) 1.000 - -
TG, (n = 49) 1.168 0.626-2.180 0.625
GG, (n = 4) 1.871 0.240-14.597 0.550
IL-13 -4729 G > A
GG, (n = 205) 1.000 - -
GA, (n = 131) 1.589 0.995-2.539 0.052
AA, (n = 51) 1.484 0.777-2.835 0.232
Multivariate logistic regression analyses were used to determine the odds ratio
(OR) and 95% Confidence Interval (CI), controlling for age, gender, G6PD
deficiency, sickle-cell trait status and presence of bacterial infections
[10,13,36-38]. The homozygous wild-type genotypes were used as reference
group for the regression analyses.
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94/222, 42.3%; P = 0.043) groups, implying that the TA
haplotype could be modulating susceptibility to SMA.
Association between IL-13 promoter haplotypes and SMA
A further multivariate logistic regression analyses, con-
trolling for the potential confounders was used to deter-
mine the association between the IL-13 promoter
haplotypes and SMA. The analyses (Table 5) revealed
that relative to the non-TA group, the carriage of the TA
(IL-13 -7402 T/-4729A) haplotype was associated with
increased susceptibility to SMA (OR; 1.564, 95% CI,
1.023-2.389, P = 0.039). However, the other haplotypes,
i.e. GG (P = 0.533) and TG (P = 0.307) did not alter sus-
ceptibility to SMA.
Functional relationship between IL-13 promoter variants
and circulating IL-13 levels
In order to explore the relationship between the individ-
ual IL-13 genotypes and functional changes in IL-13
production, circulating IL-13 levels were compared
across the different IL-13 genotypes. Results revealed
that IL-13 levels were comparable across the -7402 T/G
(P = 0.357) and -4729G/A (P = 0.438) genotypes. Further
analyses demonstrated that the IL-13 haplotypes (GG;Table 4 The distributions of IL-13 promoter haplotypes in the
Haplotypes Non-SMA (Hb ≥ 6.0 g/dL) n (%)
−7402G/-4729G 1 28 (12.6)
0 194 (87.4)
−7402 T/-4729A 1 94 (42.3)
0 128 (57.7)
−7402 T/-4729G 1 183 (82.4)
0 39 (17.6)
Haplotypes were constructed based on the IL-13 variants using the HPlus software.
carriers. Distributions of haplotypes compared between the SMA and non-SMA groP = 0.662, TA; P = 0.830, TG; P = 0.240) did not alter
changes in circulating IL-13 levels (data not presented).
Discussion
To the best of our knowledge, this is the first study to
report on the association between the IL-13 promoter
polymorphisms (−7402 T/G and -4729G/A) and sus-
ceptibility to SMA in well-defined phenotypic pediatric
populations resident in P. falciparum holoendemic
transmission region of western Kenya. Our results,
obtained from this cross-sectional study of a cohort of
parasitemic children (n = 387) aged 3–36 months in this
P. falciparum holoendemic region, revealed that none
of the individual IL-13 genotypes was associated with
susceptibility to SMA. Further analyses, however, re-
vealed that the individuals with the -7402 T/-4729A
(TA) haplotype were significantly over-represented in
the SMA group relative to non-SMA. Carriage of the
TA haplotype was associated with susceptibility to
SMA, confirming our findings that this haplotype could
confer genetic predisposition to SMA in children natur-
ally exposed to P. falciparum infection. Frequencies of
the TT genotype at the -7402 T/G genotypes was higher
in our population relative to that of the reference
Yoruba population [39], showing that this locus may be
undergoing some selective pressure in our population
either as a result of disease or any other unidentified
selection. In addition, there is likely to be additional
SNPs in linkage disequilibrium with the IL-13 variants
that may in turn lead to the observed association be-
tween the studied SNPs and SMA. It would beclinical groups







On the Table, 1 represents carriers of the haplotypes, while 0 represents non-
ups using aχ2 test.
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adjacent genes in order to further identify variants
driven by disease-related selections.
Haplotypes are important markers for identifying asso-
ciations with disease outcomes that are not identifiable
with SNPs [11]. Previous studies, using different disease
(other than SMA) models showed associations between
individual (−7402 T/G and -4729G/A) and parasitic in-
fections and allergic responses [25,30]. In the current
study, carriage of the -7402 T/-4729A (TA) haplotype
was associated with increased susceptibility to SMA.
Consistent with the finding that TA haplotype is associ-
ated with susceptibility to SMA, the presence of the
haplotype was over-represented in SMA relative to non-
SMA group. Even though the mechanism through which
carriage of the TA haplotype increases susceptibility to
SMA remain to be determined in our laboratory, we
hypothesize that the presence of the TA haplotype may
be promoting non-erythropoietic responses in children
with falciparum malaria through alteration of IL-13 pro-
moter binding of transcription factors to the IL-13 pro-
moter region. Previous studies have demonstrated that
changes that affect IL-13 and IL-13Rα1 at the D1
domain of the type II IL-4 receptor [18], leading to alter-
ations in signaling for production of IL-13 via activation
of the transcription factor signal transducer and activa-
tor of transcription 6 (STAT6) may affect erythropoi-
esis [40]. Other studies have also shown that the
IL-13Rα1 receptor forms a heterodimer with IL-4Rα
which provide signaling pathways for both IL-13 and
IL-4 [41-43]. IL-4 has further been shown to be an
erythropoietic inhibitor whose elevated production can
aggravate severe malaria [44]. As such, the presence of
the TA haplotype could be altering the gene-gene
interactions of IL-13 and IL-13Rα1, thereby promoting
enhanced IL-4 production leading to inhibition of
erythropoiesis in children with malaria. Since there
were no relationships between individual IL-13 geno-
types and haplotypes and circulating IL-13 levels in the
current study, there is likely to be additional regulators
either upstream or downstream of the IL-13 promoter
that may alter the IL-13 signaling pathway during dis-
ease. Our laboratory is currently investigating the pos-
sibility of these additional regulators in functionally
altering a milieu of immune mediators during malaria
disease pathogenesis in children.
Previous studies have demonstrated that increased IL-
13 production exacerbate infectious diseases and allergic
disorders [25,30,45,46], alter immune responses in mal-
aria [47-49], and is potentially a negative predictor of Hb
levels in children with malarial disease [17]. Even though
a previous study demonstrated that variants within the
IL-13 (−1055C/T) promoter was associated with severe
malaria in an adult Thai population [31], likely throughalterations in the binding of transcription factor (NF-
AT) on the IL-13 promoter region thereby leading to
differential production of IL-13 levels, no study to date
had determined the role of -7402 T/G and -4729G/A in
altering IL-13 production in children with malaria. We
demonstrate that these variants (genotypes and haplo-
types) do not independently alter IL-13 circulating levels
in our pediatric population. In addition, contrary to pre-
vious findings [25,47-49], circulating IL-13 levels did not
significantly differ between the SMA and non-SMA in
our cohort. Even though previous studies have addition-
ally demonstrated that IL-13 is involved in alternative
activation of macrophages, a mechanism specialized for
defense against extracellular pathogens [50], it is import-
ant to note that P. falciparum is an obligatory intracellu-
lar pathogen [51], and thus, the defense mechanism
provided by alternative activation of macrophages may
not absolutely aid in defense against it.
Furthermore, differences in the current results versus
previous findings [25,47-49] could be due to geograph-
ical and demographic differences which may concomi-
tantly be accompanied by various selective pressure.
For example, the current pediatric population is natur-
ally exposed to additional conditions such as other
parasitic infections, which may independently alter IL-
13 production [52,53]. These other parasitic infections
may (in the presence or absence of P. falciparum mal-
aria) complicate IL-13 production in relation to other
immune mediators [52,53]. It is also important to note
that infectious diseases occur through complex and
multifactorial mechanisms [10,22,36,47,53,54], and as
such, in populations in which there is likely to be mul-
tiple co-infections, it would be critical to delineate and
stratify them into those with clearly defined disease sta-
tus and carry out a comprehensive analyses of an all in-
clusive immune mediator analyses to shed more light
into those immune mediators that significantly alter
malaria disease outcomes.
Conclusion
The current study reports for the first time, the associ-
ation between the IL-13 promoter polymorphisms and
haplotypes (IL-13 -7402 T < G/ and -4729G/A) and
SMA in parasitemic children below 3 years of age in a
P. falciparum malaria holoendemic transmission area of
western Kenya. Even though the IL-13 promoter geno-
types and haplotypes did not independently alter circu-
lating IL-13 levels, carriage of the -7402 T/-4729A (TA)
haplotype appeared to be genetically predisposed to de-
velopment of SMA once the children acquired P. falcip-
arum malaria. It would be important to carry out
additional studies in independent populations experien-
cing different malaria disease outcome(s) to validate
these findings.
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